New insulin analogue launched

摘要

Insulin aspart (Novorapid), a rapid acting insulin analogue, was launched on September 21 by Novo Nordisk for the treatment of type 1 and type 2 diabetes millitus. The company says that insulin aspart has a more rapid onset and a shorter duration of action than soluble insulin and that it significantly reduces blood glucose levels during the day without excessively reducing them during the night. This gives improved glycaemic control withoutan increased risk of hypolycaemia, it says. Insulin aspart may be injected immediately before meals, rather than up to 30 minutes before meals, as required with soluble insulin.